2-Bromothiazole-4-Carboxylic Acid Methyl Ester

In early-stage small-molecule drug discovery, the rapid construction of candidate libraries containing a thiazole pharmacophore is frequently enabled by Suzuki–Miyaura, Stille, and Buchwald–Hartwig cross-coupling reactions staged on automated parallel synthesis platforms utilizing 96-well glass microreactor blocks with controlled inert gas overlay. The methyl ester at C‑4 of the thiazole ring preserves a masked carboxylate that can be hydrolytically liberated after coupling, thereby preventing coordination interference at the palladium center during the bond-forming step. Purification protocols developed for intermediates derived from 2-bromothiazole-4-carboxylic acid methyl ester routinely meet the identity and purity thresholds prescribed by ICH Q7 Section 7.3 for clinical trial material; residual palladium content is monitored against the concentration limits of ICH Q3D Elemental Impurities guideline, where the permitted daily exposure for oral administration is 100 µg/day for Pd and 15 µg/day for 4th-period transition metals introduced through catalyst carry-over. In a representative kilogram-scale coupling campaign, the bromide is charged at 1.05–1.20 molar equivalents relative to the boronic acid partner, using Pd(dppf)Cl₂·CH₂Cl₂ at 0.5–2.0 mol% loading and K₃PO₄ (2.5 equiv) in a 1,4-dioxane/water (4:1 v/v) mixture, with the jacket temperature maintained at 82±3 °C for a minimum of 18 hours under a nitrogen sweep of 15 L/h to exclude oxygen below 50 ppm in the headspace. Process analytical technology based on in-line ReactIR monitors the disappearance of the characteristic C–Br stretching band at 580 cm⁻¹, automatically triggering a quench with 5% aqueous N-acetylcysteine once conversion exceeds 98%. After phase separation over a 0.2 µm PTFE membrane filter and solvent exchange to ethyl acetate, the crude product is subjected to silica gel plug filtration followed by recrystallization from n-heptane/tetrahydrofuran (7:3) to yield a white crystalline solid with >99.2% HPLC purity (UV detection at 254 nm, area percent). The terminal products emerging from this intermediate are drug candidates belonging to the thiazole-containing kinase inhibitor class, often bearing a diaryl substitution pattern at the 2‑ and 5‑positions of the heterocycle, intended for oral solid dosage forms requiring compliance with FDA 21 CFR 211 and EMA GMP Part II for active pharmaceutical ingredient manufacture.

Why Does a 2‑Thiazole Scaffold Dominate Succinate Dehydrogenase Inhibitor Design?

The incorporation of a 2-functionalized thiazole-4-carboxylate unit into the amide bridge of modern succinate dehydrogenase inhibitor (SDHI) fungicides has been correlated with an enhanced binding affinity for the ubiquinone-binding site of complex II in the mitochondrial electron transport chain of filamentous fungi, as measured by reduced median effective concentration against Rhizoctonia solani in comparative in vitro mycelial growth assays. When 2-bromothiazole-4-carboxylic acid methyl ester is employed as the late-stage synthetic intermediate, the assembly of the final active ingredient typically proceeds through a one-pot, two-step sequence: alkaline ester hydrolysis with LiOH·H₂O (1.5 equiv) in tetrahydrofuran/water (3:1) at 40 °C for 3 h, followed by acidification with 6 M HCl to pH 2.0–2.5 and direct extractive isolation of 2-bromothiazole-4-carboxylic acid, which is then coupled to a substituted aniline using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (1.3 equiv) and 1-hydroxybenzotriazole hydrate (1.3 equiv) in N,N-dimethylformamide at 20–25 °C. The bromide is introduced at a molar ratio of 1.00–1.03 relative to the amine coupling partner to minimize excess reagent disposal cost while achieving a conversion of >99% within 16 h, verified by UPLC–MS with a C₁₈ column and 0.1% formic acid in acetonitrile/water gradient. Regulatory compliance for the technical-grade active substance requires adherence to FAO Specification 2016 and EPA 40 CFR Part 158 data requirement guidelines, including an exhaustive impurity profile where the des‑bromo analogue, generated via reductive dehalogenation during coupling, is controlled below 0.15% w/w as per the OECD No. 506 storage stability study derived from five‐batch analysis. Production-scale equipment comprises glass-lined stirred reactors (3,000 L) equipped with a retreat-blade impeller operating at 65 rpm tip speed, where the solid–liquid filtration step over a 0.5 µm sintered metal candle filter must be completed within 4 hours of the acidification endpoint to prevent precipitation of a polymorphic dihydrate that entrains 12–14% entrapped solvent and reduces isolated yield to below 70%. The resulting agrochemical active ingredient, a member of the newer pyrazole–thiazole carboxamide family targeting SDH mutations in Botrytis cinerea and Zymoseptoria tritici, is formulated as a suspension concentrate (SC) or water-dispersible granule (WG) per CIPAC Handbook Volume N methods and commercialized under maximum residue levels established by Codex Alimentarius Committee on Pesticide Residues.

The 2‑Bromothiazole‑4‑Carboxylic Acid Methyl Ester Unit Determines Carrier Transport in Organic Light‑Emitting Diode Host Materials

Electron-deficient thiazole rings substituted with an ester group exhibit a calculated lowest unoccupied molecular orbital energy of approximately −2.9 eV at the B3LYP/6-31G(d) level of theory, a value that places them at the interface between hole-blocking and electron-transport functionality in thermally activated delayed fluorescence (TADF) and phosphorescent organic light-emitting diode (OLED) stacks. 2-Bromothiazole-4-carboxylic acid methyl ester undergoes a palladium-catalyzed direct arylation at the 5‑position or a Suzuki coupling at the 2‑position to install carbazole, triphenylamine, or phenoxazine donor units, yielding bipolar host molecules with singlet–triplet energy gaps (ΔE_ST) below 0.25 eV. In a vacuum-deposited device architecture of ITO / HAT-CN (10 nm) / NPB (40 nm) / host: 8 wt% Ir(ppy)₃ (30 nm) / BCP (10 nm) / Alq₃ (30 nm) / LiF / Al, the thiazole-based host material is co-evaporated at a rate of 0.8 Å s⁻¹ from a Knudsen cell maintained at 190–210 °C under a base pressure of 5×10⁻⁷ Torr; the optimized doping concentration of the phosphorescent emitter lies in the range 5–9 wt%, determined by the iterative measurement of external quantum efficiency roll-off at luminance exceeding 1,000 cd m⁻². The bulk chemical purity required for sublimation-grade material is >99.95% by HPLC at 255 nm, with sodium, iron, and chloride ion content held below 1.0 ppm each as verified by inductively coupled plasma mass spectrometry, thereby meeting the semiconductor-grade purity criteria aligned with SEMI Standard C63-0320 and the restricted substance provisions of EU RoHS Directive 2011/65/EU Annex II. Prior to device integration, the material is purified in a three-zone horizontal glass tube furnace under a temperature gradient of 10 °C cm⁻¹, with the primary sublimation zone at 165±2 °C and a cold finger temperature of 25 °C, repeated over two cycles; the first-cycle heavy-metal residue is discarded and only the middle-cut fraction is used for thin-film fabrication. The terminal application is a green-phosphorescent OLED display panel with a maximum current efficiency of 72 cd A⁻¹ and an operational lifetime LT₉₅ of 8,000 hours at 1,000 cd m⁻², produced under cleanroom class ISO 14644-1 Class 5 conditions and encapsulated with a glass-frit seal to maintain moisture ingress below 5×10⁻⁶ g m⁻² day⁻¹.

The crystallographic registry of carboxylate-functionalized thiazole ligands with copper(II) paddlewheel secondary building units (SBUs) has been systematically exploited to construct isoreticular metal–organic frameworks (MOFs) possessing hexagonal channel systems with pore limiting diameters tunable between 6.4 Å and 11.2 Å. Hydrolysis of 2-bromothiazole-4-carboxylic acid methyl ester to the free carboxylic acid is performed under non-aqueous conditions using trimethylsilyl iodide (3.0 equiv) in anhydrous acetonitrile at 60 °C for 8 hours under argon, followed by quenching with methanol and evaporation to dryness; the hydrolysis path is selected over conventional NaOH-mediated saponification in order to avoid generation of the 2-hydroxy by-product that competes with bromide for the metal coordination sphere. The resulting 2-bromothiazole-4-carboxylic acid ligand is dissolved in N,N-dimethylformamide together with Cu(NO₃)₂·3H₂O at a molar ratio of 1:1.5 (ligand:metal) and HNO₃ (0.2 M) as modulator, heated in a sealed PTFE-lined 100 mL autoclave at 105 °C for 36 hours with a ramp rate of 0.5 °C min⁻¹. The cubic-shaped blue crystals are solvent-exchanged with methanol over 72 hours and activated under dynamic vacuum (10⁻⁴ mbar) at 120 °C to yield a Brunauer–Emmett–Teller surface area of 1,420–1,580 m² g⁻¹ as determined by N₂ sorption at 77 K in accordance with ISO 9277:2022. The bromide handle at the 2‑position of the thiazole ring survives the solvothermal synthesis conditions intact and remains available for post-synthetic modification via click chemistry or Sonogashira coupling, enabling the introduction of alkyne-terminated imaging modalities. For the intended use as a stationary phase additive in gas chromatographic separation of CO₂/CH₄ mixtures, the material is pelletized under 2.5 MPa pressure and sieved to 250–425 µm particle size fraction. The terminal device is a packed-bed column certified under ASTM D7164-10 for break-through capacity measurement, and the MOF sorbent is assessed for compliance with REACH Regulation EC 1907/2006 when supplied in quantities above 1 metric ton per year. Long-term cycling stability tests in a 10-column vacuum swing adsorption rig at 35 °C and 1.7 bar feed pressure demonstrate a sustained working capacity of 2.8 mol kg⁻¹ over 600 cycles with less than 4% amine-related degradation by-product accumulation in the downstream pipeline, attributed to the absence of labile ester groups in the activated framework.

Engineering Fluorescent Thiazole Probes for Cellular Thiol Quantification

The pronounced solvatochromic shift exhibited by 2,4‑disubstituted thiazole derivatives upon reaction with intracellular glutathione (GSH) has been exploited in the design of ratiometric fluorescent probes with excitation/emission maxima at 405/490 nm and 488/535 nm for the thiol-bound and unbound states, respectively. A representative probe is assembled by converting 2-bromothiazole-4-carboxylic acid methyl ester to the corresponding 2‑piperazino derivative via nucleophilic aromatic substitution with piperazine (2.0 equiv) in ethanol at 65 °C for 12 hours in the presence of titanium isopropoxide (0.1 equiv), followed by condensation of the ester with a dansyl hydrazide fragment. The critical formulation requirement for in vitro imaging applications is the elimination of residual palladium used in prior synthetic steps, which is accomplished by treatment with Si-thiol scavenger resin (loading 1.2 mmol g⁻¹) at 3% w/w relative to the probe mass, stirred for 4 hours at ambient temperature and filtered through a 0.22 µm polypropylene syringe filter; the confirmed palladium level of <0.5 ppm via ICP-MS validates the material as suitable for cell-based assays under ISO 10993-1:2018 biological evaluation guidelines when intended for diagnostic reagent use. In a typical live-cell microscopic assay, the probe is applied at a final concentration of 2–5 μM in HEPES-buffered phenol red-free DMEM, and the ratiometric response (I₅₃₅/I₄₉₀) is calibrated against GSH standards spanning 0.1–10 mM with a linear dynamic range coefficient of determination R² > 0.995. During scale-up synthesis for reagent kit manufacture, the process employs a 500 mL jacketed reactor with PTFE baffles and a overhead stirrer at 300 rpm, with successive liquid-liquid extractions using dichloromethane and deionized water (conductivity <0.5 µS cm⁻¹); the organic layer is passed through a bed of magnesium sulfate and concentrated on a rotary evaporator operated at 40 °C bath temperature and 30 mbar vacuum to avoid degradation observed above 45 °C. The dried solid is stored under argon in amber glass vials with PTFE-lined caps at −20 °C and shipped on dry ice; stability studies per ICH Q1A(R2) demonstrate less than 0.5% area increase of the oxidized by-product after 18 months at −20 °C. The final products are ready-to-use fluorescent thiol quantitation kits containing 1 mg aliquots of the lyophilized probe, supplied with a certificate of analysis referencing ISO 13485:2016 for medical device quality management systems when marketed for research use in primary neuronal cultures and biopsied tissue samples.

When the Ester Functionality Survives Hydrolysis in Peptide Bond Mimicry

A distinct application trajectory where the methyl ester of 2-bromothiazole-4-carboxylic acid remains intact throughout the synthetic sequence involves its direct incorporation into peptidomimetic backbone replacements designed to resist protease-mediated cleavage in cyclic peptide scaffolds. The bromide serves as the anchor point for on-resin Sonogashira conjugation with propargylglycine-containing sequences, while the ester group is deliberately preserved as a non-ionizable mimic of the aspartic acid side chain, occupying a comparable van der Waals volume of 72.5 ų versus 69.8 ų for the carboxylate anion as computed by molecular mechanics. Solid-phase synthesis is performed on Rink amide AM resin (loading 0.48 mmol g⁻¹) using Fmoc chemistry, where 2-bromothiazole-4-carboxylic acid methyl ester is first coupled as the C-terminal cap with HBTU (4.0 equiv) and N,N-diisopropylethylamine (8.0 equiv) in DMF at 25 °C for 45 minutes, followed by the palladium-catalyzed coupling step carried out directly on the swollen resin beads with Pd(PPh₃)₄ (0.15 equiv) and CuI (0.30 equiv) in degassed piperidine/DMF (1:4) at 50 °C under microwave irradiation (70 W, 8 minutes). The dosage ratio of the thiazole ester fragment to the supported peptide is controlled at 1.8–2.2 equivalents based on the free amino group substitution level, as determined by quantitative Kaiser test (ε₅₇₀ = 15,000 M⁻¹ cm⁻¹). Post-cleavage deprotection with reagent K (TFA/thioanisole/water/phenol/EDT, 82.5:5:5:5:2.5) for 3 hours produces the crude cyclic peptide, which is purified by preparative reverse-phase HPLC on a C₁₈ column (250 × 21.2 mm, 5 µm) with a linear gradient of 10–60% acetonitrile in water containing 0.1% TFA over 40 minutes at 20 mL min⁻¹. Stringent control of residual solvent limits is required for toxicological evaluation: the levels of acetonitrile, DMF, and thioanisole are verified to fall below 410 ppm, 880 ppm, and 200 ppm respectively, consistent with ICH Q3C Options 1 and 2 for products administered by subcutaneous injection. The purified monocyclic peptidomimetic is lyophilized from 0.1% aqueous acetic acid to a powder with >98.5% purity (HPLC at 220 nm) and stored at −80 °C in low-retention polypropylene tubes. The target molecule functions as a selective and covalent inhibitor of the chymotrypsin-like active site of the 20S proteasome in vitro, exhibiting an inhibition constant K_i of 23 nM, and is subjected to a battery of regulatory in vitro ADMET assays aligned with OECD 417 principles on toxicokinetics prior to advancement into preclinical development under FDA INDA 21 CFR 312.